Page last updated: 2024-11-02

oxonic acid and Local Neoplasm Recurrence

oxonic acid has been researched along with Local Neoplasm Recurrence in 311 studies

Oxonic Acid: Antagonist of urate oxidase.

Research Excerpts

ExcerptRelevanceReference
"We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events."9.20Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015)
"To date, gemcitabine-based or fluoropyrimidine-based regimens are recommended for unresectable advanced biliary tract cancer."9.20Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. ( Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K, 2015)
"A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)."9.20Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015)
"Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)."9.20Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015)
"A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer."9.17A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013)
"We aimed to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the addition of S-1, an oral fluorouracil derivative, to gemcitabine and cisplatin combination therapy, which is the current standard treatment for advanced biliary tract cancer."9.16Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D, 2012)
"We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer."9.15A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011)
"To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer."9.15A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011)
"This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer."9.15Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011)
"This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens."9.12A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006)
"A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients."8.83[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006)
"Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)."8.02Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021)
"5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer."7.80Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014)
"Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)."7.78An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012)
"Patients with HER2-negative and endocrine treatment-resistant breast cancer with metastasis or recurrence after surgery were randomly assigned to receive first-line taxane or S-1."5.27Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer. ( Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T, 2018)
"We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events."5.20Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015)
"To date, gemcitabine-based or fluoropyrimidine-based regimens are recommended for unresectable advanced biliary tract cancer."5.20Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. ( Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K, 2015)
"A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)."5.20Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015)
"Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)."5.20Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015)
"A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer."5.17A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013)
"We aimed to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the addition of S-1, an oral fluorouracil derivative, to gemcitabine and cisplatin combination therapy, which is the current standard treatment for advanced biliary tract cancer."5.16Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D, 2012)
"We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer."5.15A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011)
"To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer."5.15A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011)
"This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer."5.15Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011)
"This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens."5.12A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006)
" Major toxicities were leukopenia (38%), anorexia (27%), increased total bilirubin concentration (25%) and diarrhea (24%)."5.10[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003)
"A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients."4.83[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006)
"Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)."4.02Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021)
"Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)."3.91S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019)
" The first group was given tailored CPT-11, adjusting individual optimal dosage using toxicity-based grading as an index in combination with TS-1, and the second group was given standard TS-1 treatment."3.81[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)]. ( Kitajima, M; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Toge, T, 2004)
"We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium)."3.80Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study. ( Higashino, M; Ichihara, S; Kawata, R; Lee, K; Nishikawa, S; Uesugi, Y, 2014)
"5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer."3.80Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014)
"Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)."3.78An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012)
"High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer."3.74[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007)
"The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive."3.11Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. ( Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z, 2022)
"Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated."3.01Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). ( Doki, Y; Eguchi, H; Haraguchi, N; Ide, Y; Kim, H; Kudo, T; Matsuda, C; Mizushima, T; Murata, K; Nakata, K; Nishizawa, Y; Okamura, S; Satoh, T; Uemura, M, 2021)
" Most frequent (>10%) grade 3/4 treatment-related adverse events were neutropenia (14."2.90Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A ( Azuma, M; Boku, N; Chen, LT; Cho, H; Chung, HC; Fumita, S; Hara, H; Kang, WK; Kang, YK; Kato, K; Komatsu, Y; Lee, KW; Minashi, K; Ryu, MH; Tsuda, M; Yamaguchi, K, 2019)
"The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established."2.90Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. ( Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S, 2019)
"Recent gastric cancer clinical trials have aimed to establish the efficacy of combination therapy over monotherapy, however, the role for genomic biomarkers in these trials has remained largely unexplored."2.87Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. ( Das, K; Imamura, H; Nishikawa, K; Sugimoto, N; Taguri, M; Tan, P; Tsuburaya, A; Yoshida, K, 2018)
"Sixteen patients (48."2.87A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. ( Atagi, S; Azuma, M; Goto, H; Haku, T; Hanibuchi, M; Kakiuchi, S; Kawano, H; Kondo, M; Nishioka, Y; Nokihara, H; Ogushi, F; Otsuka, K; Sakaguchi, S; Shimizu, E; Toyoda, Y, 2018)
" This study evaluated the efficacy of intensity modulated radiotherapy in combination with gemcitabine and S-1 as neoadjuvant chemoradiotherapy (NACRT) for borderline-resectable pancreatic cancer with arterial involvement (BR-A)."2.84A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. ( Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A, 2017)
"However, the high recurrence rate makes gastric cancer difficult to cure by surgery alone."2.82A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, KR; Nam, TK; Park, YK; Ryu, SY; Shim, HJ, 2016)
"Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year."2.82A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ( Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K, 2016)
"Irinotecan was administered intravenously over the course of 90 minutes on day 1, and S-1 was given orally in 2 divided doses from days 1 to 14 of a 21-day cycle."2.82Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy. ( Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E, 2016)
" The safety and dosage of S-1 combined with postoperative radiotherapy have not yet been evaluated."2.80Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. ( Bi, F; Cao, D; Chen, Y; Gou, HF; Li, Q; Li, ZP; Liu, JY; Peng, XC; Qiu, M; Shen, YL; Wang, X; Xu, F; Yang, Y; Yi, C; Zhao, YQ, 2015)
"Our study indicates that S-1 monotherapy is safe and well tolerated in chemotherapy-naïve elderly patients with AGC, but exerts limited activity when given using a tailor-made dosing strategy based on renal function."2.79Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). ( Furukawa, H; Iijima, S; Imamura, H; Imano, M; Kimura, Y; Kishimoto, T; Kurokawa, Y; Maruyama, K; Morimoto, T; Otsuji, T; Takiuchi, H; Yamashita, K, 2014)
"As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone."2.79Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). ( Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K, 2014)
"Pancreatic cancer is one of the most aggressive cancers with a median survival time (MST) of <6 months in chemotherapy-resistant patients."2.78A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. ( Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S, 2013)
"Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases."2.78Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013)
"Patients with advanced/recurrent gastric cancer were randomized to receive tailored irinotecan and S-1 (arm A) therapy or S-1 therapy alone (arm B)."2.76Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ( Kimura, Y; Kitajima, M; Komatsu, Y; Oda, H; Saji, S; Sakamoto, J; Sakata, Y; Sakurai, J; Tajima, Y; Takahashi, M; Takahashi, Y; Tamura, S; Tatebe, S; Wakasugi, T, 2011)
"Patients with hormone-resistant breast cancer are assigned to either TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period) or standard chemotherapy (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)."2.75Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). ( Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T, 2010)
"The survival rate of patients with squamous cell carcinoma of the head and neck was 59."2.74Outpatient chemotherapy with S-1 for recurrent head and neck cancer. ( Shinden, S; Shiotani, A; Watabe, T; Yamashita, T, 2009)
"This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer."2.74Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. ( Egashira, A; Emi, Y; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Sadanaga, N; Takahashi, I, 2009)
"Paclitaxel was administered intravenously on days 1, 8 and 15, at an initial dose of 40 mg/m(2), stepping up to 70 mg/m(2) in 10-mg/m(2) increment."2.74Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. ( Fukunari, H; Hatano, T; Hayashi, T; Inada, S; Kawauchi, Y; Nikkuni, K; Nishimura, A; Sato, T; Shimizu, T; Sugita, M; Takahashi, S; Tomidokoro, T; Yanagi, M; Yoshida, H, 2009)
"Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine."2.73Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. ( Arai, K; Fujii, M; Furukawa, H; Higashino, M; Imamura, H; Kinoshita, T; Kurita, A; Nakajima, T; Nashimoto, A; Ohashi, Y; Sakuramoto, S; Sasako, M; Yamaguchi, T; Yamamura, Y, 2007)
"Lentinan (LNT) is a beta-glucan known to have a life-prolonging effect in combination with chemotherapy for patients with unresectable or recurrent gastric cancer."2.72[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. ( Kashimura, H; Kashiwagi, H; Mitsumori, N; Nimura, H; Takahashi, N; Takayama, S; Yanaga, K, 2006)
"Paclitaxel was given intravenously on days 1, 8, and 15, starting with a dose of 40 mg m-2 day-1."2.72Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. ( Aihara, R; Asao, T; Haga, N; Kamiyama, Y; Kuwano, H; Mochiki, E; Nakabayashi, T; Nakamura, J; Ohno, T; Ohsawa, H; Ojima, H; Takeuchi, K, 2006)
" With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen)."2.71A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. ( Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H, 2003)
" A biological response modifier, lentinan (LNT) prolonged the survival period of patients with UARG when combined with tegafur (FT)."2.71[Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer]. ( Atomi, Y; Kusano, M; Mitsumori, N; Nakajima, M; Nimura, H; Suzuki, S; Tokunaga, A; Tsukagoshi, S; Yoshiyuki, T, 2003)
"We designed an outpatient regimen consisting of fractional cisplatin in combination with S-1, a novel oral fluoropyrimidine derivative for the treatment of recurrent or advanced gastric cancer and conducted a phase I study to determine the dose limiting toxicities (DLTs) and recommended dose (RD)."2.71Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study. ( Hiki, N; Imamura, K; Kaminishi, M; Mafune, K; Shimoyama, S; Yamaguchi, H, 2005)
"Paclitaxel was infused over 1 h on days 1, 8, and 15."2.71Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. ( Ichikawa, D; Kakihara, N; Koizumi, K; Kurioka, H; Morii, J; Morita, S; Nakamura, K; Nishiyama, M; Sakamoto, J; Shimotsuma, M; Takenaka, A; Ueda, Y; Yamagishi, H; Yamashita, T, 2005)
"TS-1 is a promising drug for gastric cancer with peritoneal dissemination."2.70[The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002)
"There was no gastric cancer progression."2.48Hypomanic episode during recurrent gastric cancer treatment: report of a rare case and literature review. ( Araki, K; Ishida, M; Kaneta, T; Matsunaga, M; Miwa, K; Nakayama, H; Narabayashi, M; Noguchi, T; Onishi, H; Sasaki, Y; Shimada, K; Sunakawa, Y, 2012)
" The main adverse events (AEs) of anlotinib combined with S-1 were fatigue (58."1.62Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy. ( Cai, J; Liu, A; Luo, Y; Zhou, S, 2021)
"Hereby, we report a case of type 4 gastric cancer with peritoneal dissemination successfully treated with conversion surgery after intensive SOX chemotherapy."1.62[A Case of Type 4 Gastric Cancer with Peritoneal Dissemination Successfully Treated with Conversion Surgery after Intensive S-1 plus Oxaliplatin Chemotherapy]. ( Iwasaki, K; Kitamura, K; Koide, N; Koyama, M; Matsumura, T; Nomori, H; Obana, A; Sato, Y; Suwa, T; Usui, S; Yoshida, R, 2021)
"The Japanese Gastric Cancer Treatment Guidelines recommend S-1 and S-1 plus docetaxel as postoperative chemotherapy for pathological stage II and III gastric cancer (GC)."1.62Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Noda, M; Ohtsuka, T; Okubo, K; Sasaki, K; Tanaka, T; Tsuruda, Y, 2021)
"Lymph node metastasis was an independent risk factor for both locoregional (P < 0."1.62Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. ( Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H, 2021)
" Thirty-two patients developed 54 events of CRT-related adverse events, including only one patient with a grade 3 event (stomatitis)."1.62Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer. ( Doki, Y; Eguchi, H; Kitakaze, M; Miyoshi, N; Mizushima, T; Murata, K; Noura, S; Ohue, M; Takahashi, H; Tei, M; Uemura, M, 2021)
" Although weekly paclitaxel followed by reduced S-1 dosage was introduced after surgery, the recurrent mass was observed in the para-aortic region after 2 years."1.56[A Case of Long-Term Survival with Far Advanced Gastric Cancer after Multidisciplinary Treatments, including Conversion Surgery]. ( Akiyama, T; Fujiwara, Y; Higashida, M; Iwamoto, R; Kinoshita, S; Kitagawa, S; Kubota, H; Mineta, S; Okada, T; Okamoto, Y; Tsuruta, A; Ueno, M; Ueno, T; Watanabe, Y, 2020)
"A large proportion of recurrent cervical cancer (RCC) patients present with poor performance status (PS) after comprehensive treatments, which usually prevents them from opting for clinical trials."1.56Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series. ( Jiang, SN; Shang, YP; Wang, ZM; Xu, XJ, 2020)
"Forced expression of CDO1 in gastric cancer cell lines was assessed using the JC-1 assay."1.56Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer. ( Harada, H; Hiki, N; Hosoda, K; Nishizawa, N; Soeno, T; Ushiku, H; Yamashita, K; Yokoi, K, 2020)
"Some postoperative gastric cancer patients have to terminate systemic intravenous chemotherapy early due to adverse drug reactions."1.51The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients. ( Cao, T; Han, X; Li, G; Li, H; Liu, H; Wang, C; Yan, L, 2019)
"We report a case of advanced gastric cancer with stenosis under severe malnutrition, in which nutritional treatment along with chemotherapy using an elemental diet(ED)tube led to complete resection of the tumor."1.51[A Case of Curative Resection of Locally Advanced Gastric Cancer after Nutrition Therapy and Chemotherapy with S-1 and Oxaliplatin Using Elemental Diet Tube]. ( Deguchi, S; Hirakawa, K; Hori, T; Ishikawa, T; Masuda, G; Nakata, B; Sakimura, C; Tani, N; Tendo, M, 2019)
"A 60s man was diagnosed with rectal cancer and underwent low anterior resection of the rectum."1.51[A Case of Curatively Resected Locally Recurrent Rectal Mucinous Adenocarcinoma Followed by Preoperative Chemoradiotherapy]. ( Ishida, T; Kajiwara, T; Kamei, T; Karasawa, H; Kohyama, A; Naitoh, T; Ohnuma, S; Sato, K; Suzuki, H; Unno, M; Watanabe, K, 2019)
"A-67-year old man was diagnosed with gastric cancer and a liver tumor."1.51[A Case of Gastric Endocrine Carcinoma with a Huge Liver Metastasis]. ( Kawaoka, T; Kubo, H; Miyahara, M; Nabeya, M; Nishida, Y; Saeki, S; Sasaki, S; Tamesa, T; Tokunou, K; Yamamoto, S; Yamashita, Y, 2019)
"We report a case of advanced gastric cancer with right gastroepiploic vein tumor thrombus treated using preoperative S-1 plus cisplatin(CDDP)in which pathological complete response was achieved."1.51[A Case of Advanced Gastric Cancer with Right Gastroepiploic Vein Tumor Thrombus Treated by Preoperative S-1 plus CDDP That Resulted in Pathological Complete Response]. ( Arai, S; Goseki, N; Koike, M; Kuwabara, H; Nakamura, N; Sanada, T; Sato, T; Tomi, Y; Yoshida, T, 2019)
"Although the prognosis ofypStage Ⅰgastric cancer was comparatively good, the regimen and courses ofpostoperative chemotherapy should be evaluated in a prospective study."1.51[Adjuvant Chemotherapy and the Prognosis of ypStageⅠ Gastric Cancer]. ( Akamaru, Y; Azama, T; Kitada, M; Morimoto, O; Munakata, K; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R, 2019)
"A scirrhous gastric cancer was found, and he was introduced to us."1.51[Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases]. ( Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Noma, T; Takahashi, T; Tanaka, K; Yamasaki, M, 2019)
"We report a case of recurrent gastric cancer that was successfully treated by S-1 chemotherapy."1.51[A Case of Recurrent Gastric Cancer Successfully Treated by S-1 Chemotherapy]. ( Hata, M; Hoshino, H; Imamoto, H; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Ogino, T; Okano, M; Okuyama, M; Tanizaki, K; Tsujinaka, T, 2019)
"Among gastric cancer patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy, patients who experienced a recurrence while receiving adjuvant therapy or within 6 months after completion and started systemic chemotherapy at four institutions between 2005 and 2015 were eligible."1.51Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. ( Chin, K; Hara, H; Hasegawa, H; Hirao, M; Kadowaki, S; Mitani, S; Muro, K; Nishikawa, K; Tajika, M; Takahari, D; Wakatsuki, T, 2019)
"She was diagnosed with clinical Stage Ⅳ gastric cancer(cT3N2M1H1)."1.51[A Case of Advanced Gastric Cancer with Pathological Complete Response after Chemotherapy(S-1/Cisplatin)]. ( Egawa, H; Fukunaga, T; Ishibashi, Y; Kaji, S; Kajiyama, Y; Kanda, S; Kohira, Y; Oka, S; Sakamoto, K; Yube, Y, 2019)
"Although, gastric cancer is one of the most common cancers worldwide, alpha-fetoprotein (AFP) producing human epidermal growth factor receptor 2 (HER2) positive gastric cancers are rare."1.48Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2. ( Arakawa, Y; Hayashi, K; Nagasaki, E; Nakada, K; Tamura, M; Uwagawa, T; Yano, S, 2018)
"However, severe neutropenia is often observed (40%) during this therapy."1.48Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer. ( Kawachi, S; Kimura, M; Shinoda, Y; Usami, E; Yoshimura, T, 2018)
"In the latest Japanese gastric cancer treatment guidelines, PAM plus paclitaxel(PTX)was positioned as a second-line chemotherapy for advanced gastric cancer."1.48[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel]. ( Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T, 2018)
"Dissemination of gastric cancer tends to be difficult to treat and has a poor prognosis."1.48[Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma]. ( Ajioka, Y; Alexey, A; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A, 2018)
" The patient received gamma knife stereotactic radiosurgery (GKSRS) combined with S-1 treatment."1.46Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report. ( Dong, X; Du, F; Tang, S; Wei, H; Wei, J, 2017)
"Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed."1.46Usefulness of chemoradiotherapy for inoperable gastric cancer. ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017)
"The prognosis of advanced gastric cancer was significantly related to the start of S-1 adjuvant treatment within 6 weeks after surgery."1.43S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer. ( Egashira, A; Ikeda, Y; Kinjo, N; Minami, K; Morita, M; Okamura, T; Sakaguchi, Y; Toh, Y; Yamaguchi, S; Yamamoto, M, 2016)
"Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled."1.40Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. ( Fuse, N; Goto, M; Hamaguchi, T; Ito, S; Katai, H; Konishi, M; Sano, T; Sasako, M; Shirao, K; Takahari, D; Tanigawa, N; Terashima, M; Yasui, H; Yoshimura, K, 2014)
"Management of peritoneal disseminated gastric cancer (GC) remains a challenging problem."1.40Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. ( Canbay, E; Hirano, M; Ichinose, M; Ishibashi, H; Mizumoto, A; Sako, S; Takao, N; Yonemura, Y, 2014)
"The optimal radiotherapy technique and combination with systemic therapy in locally advanced gastric cancer patients are far from being resolved despite the fact that radiochemotherapy is becoming more attractive in contemporary clinical practice."1.40Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients. ( Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q, 2014)
" Most adverse events were mild."1.40Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis. ( Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014)
"The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009."1.40Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014)
"The standard treatment for stage IV gastric cancer is chemotherapy, but outcomes remain poor."1.40Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients. ( Kiyozaki, H; Rikiyama, T; Saito, M; Suzuki, K; Takata, O, 2014)
"Because we suspected septic pulmonary embolism related to the venous port, we removed the venous port promptly and administered antibiotics with a broad spectrum."1.39[A case of a septic pulmonary embolism-related implanted central venous port]. ( Daga, H; Miyamoto, N; Nishijima, M; Okada, H; Sumitani, M; Syoji, S; Taira, K; Takeda, K; Tokunaga, S; Tsuda, M, 2013)
"It may be useful for esophageal squamous cell carcinoma (ESCC); however, there are insufficient data."1.39S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. ( Akutsu, Y; Hanaoka, T; Hoshino, I; Kono, T; Matsubara, H; Narushima, K; Qin, W; Semba, Y; Tochigi, T; Uesato, M, 2013)
" Pharmacists should consider reducing the treatment dosage and providing nutritional support in such cases."1.39Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer. ( Kaneoka, Y; Kimura, M; Sugiyama, T; Teramachi, H; Tsuchiya, T; Usami, E; Yasuda, T; Yoshimura, T, 2013)
"In resectable advanced laryngeal cancer, S-1 adjuvant chemotherapy is an effective and feasible treatment option to control distant metastases following reduced RADPLAT."1.38Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer. ( Endo, K; Kondo, S; Murono, S; Wakisaka, N; Yoshizaki, T, 2012)
"In patients with stage II/III gastric cancer, tumors often recur even after curative D2 gastrectomy followed by adjuvant S-1 chemotherapy."1.37Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. ( Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T, 2011)
"Gluteal recurrence of the original gastric cancer was suggested, and systemic chemotherapy consisting of S-1 at 100 mg/day (3 weeks on, 1 week off) and CDDP (day 8) was started."1.37Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination. ( Deguchi, R; Iwata, Y; Mine, T; Numata, M; Ogasawara, F; Ohtani, Y; Sakuma, T; Sato, S; Takashimizu, S, 2011)
"S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0."1.36Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? ( Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T, 2010)
"Paclitaxel 50mg/m2 was administered on days 1 and 8."1.36[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)]. ( Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H, 2010)
"The treatment for hepatocellular carcinoma with distant metastasis remains unclear."1.36[A successful case of S-1 chemotherapy for bilateral pulmonary recurrence of hepatocellular carcinoma long after hepatectomy]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2010)
"Patients with residual tumors after the initial treatment had a response rate of 47."1.36[Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment]. ( Katsuno, M; Sato, N; Sugio, Y; Tachibana, S; Tani, Y; Watanabe, N; Zusho, H, 2010)
"Lymph node metastasis was confirmed."1.36[A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin]. ( Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Maeura, Y; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S, 2010)
"We report a case of local recurrent colorectal cancer that has been treated successfully with low-dose oral chemotherapeutic agent."1.36[A case of local relapsed rectal cancer responding to low-dose S-1]. ( Fujita, S; Ikeda, N; Kanamura, T; Kojima, Y; Nakagawa, K; Ueno, M, 2010)
"To cure intrahepatic cholangiocarcinoma (ICC), only a surgical resection is the potential treatment at present."1.36[A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection]. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tanida, T; Umeshita, H; Wada, H, 2010)
"A 65-year-old man with common bile duct cancer was treated by pylorus-preserving pancreaticoduodenectomy with D2 lymph node dissection."1.35[A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy]. ( Fukao, K; Irabu, S; Kasagawa, T; Kusashio, K; Matsumoto, M; Nobumoto, D; Suzuki, M; Tashima, Y; Tonooka, T; Udagawa, I; Yasutomi, J, 2008)
"A type 2 advanced gastric cancer was observed on the gastric antrum."1.35[A case of early recurrence with multiple liver metastases after curative operation of gastric cancer successfully treated by S-1/CDDP combination chemotherapy]. ( Akiho, H; Goto, A; Itaba, S; Murao, H; Nagai, E; Nakamura, K; Segawa, Y; Takayanagi, R; Tokunaga, N; Yoshinaga, S, 2008)
" Five patients showed grade 3 and 4 adverse reactions, all hematological."1.35Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. ( Ishikawa, K; Suzuki, S, 2009)
" It is also considered necessary to adjust the dosage of the anticancer drugs and the dosing period for patients with a PS of 2 when preparing a chemotherapeutic regimen for digestive carcinoma, including stomach carcinoma."1.35[Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer]. ( Akasaka, O; Anan, H; Ando, T; Iwase, S; Kasama, M; Koh, R; Matsueda, R; Miwa, H; Morita, S, 2009)
"We describe a case of locally recurrent rectal cancer that was successfully treated with radiation and chemotherapy with S-1; this treatment resulted in long-term survival of the patient with a good performance status."1.35[A case of locally recurrent rectal cancer responding to radiation and chemotherapy with S-1]. ( Baba, H; Fujiwara, N; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Tamai, S, 2009)
" He was treated with single agent S-1 in 10 courses on a 4-week dosing regimen with a 2-week interval."1.35[A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy]. ( Iwanaga, T; Iwasaki, Y; Matsumoto, H; Matsumura, H; Nakano, D; Ohashi, M; Takahashi, K; Yamaguchi, T, 2009)
"But second primary gastric cancer was detected in antrum 26 months after primary therapy."1.35[A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice]. ( Fukushima, Y; Hashimoto, K; Hiraki, M; Matsumoto, S; Matsuyama, J; Morimoto, T; Morita, S; Naitou, A; Nishishou, I; Nomura, T; Sasaki, Y; Yokoyama, S, 2009)
" But, we dosed down with S-1 due to severe diarrhea."1.35[A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. ( Akitake, H; Ebisui, C; Fujimoto, T; Hama, N; Kashiwazaki, M; Konishi, M; Maekawa, T; Ookubo, K; Ootsuka, M; Taniguchi, M; Tsujie, M; Yoshioka, S, 2009)
"Recently, chemotherapy against gastric cancer has been diversified with an appearance of new agents such as S-1, capecitabine, CPT-11, oxaliplatin, paclitaxel and docetaxel."1.35[A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy]. ( Ami, K; Andou, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kurokawa, T; Nagahama, T; Ohara, T; Tei, S, 2009)
"An 82-year-old female with unresectable colon cancer accompanied by multiple lung metastasis was treated with S-1."1.35[An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response]. ( Arita, A; Fujimoto, M; Mochizuki, K; Sakai, Y, 2008)
"Current therapy for advanced pancreatic cancer focuses largely on gemcitabine."1.35Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. ( Alsamarai, S; Furuie, T; Saif, MW; Urrea, PD; Zergebel, C; Zhang, J, 2008)
" This article identifies the risk factors for severe adverse events of S-1 from nationwide survey data."1.34Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. ( Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2007)
" The patient was treated with S-1 combined with CPT-11."1.34[An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11]. ( Doi, M; Egawa, T; Hayashi, S; Ito, Y; Kitano, M; Nagashima, A; Sekine, K; Shimizu, M; Yoshii, H, 2007)
"A 58-year-old man with gastric cancer who had undergone distal gastrectomy on February 8, 2001 was revealed to have anorexia, and was diagnosed with a local recurrence in anastomosis by upper GI examination in August 2003."1.33[Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report]. ( Fujii, M; Kasakura, Y; Kochi, M; Morishita, Y; Sato, K; Takayama, T; Yamagata, M, 2005)
" There were less severe adverse events concerning paclitaxel despite of the second line therapy of TS-1, and 80 percent of all therapeutic courses was at an outpatient clinic."1.33[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination]. ( Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K, 2005)
"The patient diagnosed as recurrent pancreatic cancer was treated with UFT combined gemcitabine (GEM) chemotherapy."1.33[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease]. ( Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T, 2006)
" We carried out 4-week administration of 80-120 mg/day of TS-1 according to body surface area, followed by a 2-week discontinuation, then repeated administration which adjusting the dosage according to the incidence of side effects, and discussed the antitumor effects and adverse events."1.33[Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer]. ( Hatori, S; Imada, T; Kunisaki, C; Makino, T; Ohshima, T; Rino, Y; Suda, T; Takanashi, Y; Yamada, R; Yamazaki, Y, 2006)
" The adverse effects observed were grade 3 leukopenia in 2 patients (11."1.33[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy]. ( Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R, 2006)
"We treated a recurrent gastric cancer patient with chronic renal failure who developed grade 2 HFS, grade 2 conjunctivitis and grade 3 stomatitis soon after TS-1 administration."1.32[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003)
" TS-1 was administered with the usual dosage and dose regimen."1.32[A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital]. ( Abe, S; Kitago, M; Kobayashi, T; Kojima, M; Kurihara, H; Nakamura, T; Ogihara, T; Tamura, H, 2003)
"Although the prognosis of recurrent gastric cancer with peritoneal dissemination was extremely poor, this case might suggest a possibility that intensive therapies are useful in maintaining the quality of life and improving survival."1.32[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T, 2004)

Research

Studies (311)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.32)18.2507
2000's96 (30.87)29.6817
2010's177 (56.91)24.3611
2020's37 (11.90)2.80

Authors

AuthorsStudies
Hosoda, K3
Fukushima, K1
Shimizu, A1
Motoyama, H1
Kubota, K4
Notake, T1
Sugenoya, S1
Hayashi, H2
Yasukawa, K1
Kobayashi, R4
Soejima, Y1
Mei, Y1
Shi, M1
Zhu, Z2
Yuan, H1
Yan, C1
Li, C1
Feng, T1
Yan, M1
Zhang, J2
Miyajima, N1
Ragab Eissa, I1
Abdelmoneim, M1
Naoe, Y1
Ichinose, T1
Matsumura, S1
Bustos-Villalobos, I1
Mukoyama, N1
Morimoto, D1
Shibata, M1
Takeuchi, D1
Tsunoda, N1
Kikumori, T1
Tanaka, M2
Kodera, Y5
Kasuya, H1
Cai, J1
Zhou, S1
Luo, Y1
Liu, A1
Soeno, T2
Katoh, H1
Ishii, S1
Ushiku, H3
Hiki, N6
Watanabe, M3
Yamashita, K3
Yamaguchi, T9
Takashima, A2
Nagashima, K1
Makuuchi, R1
Aizawa, M1
Ohashi, M7
Tashiro, K1
Yamada, T2
Kinoshita, T2
Hata, H2
Kawachi, Y1
Kawabata, R1
Tsuji, T2
Hihara, J6
Sakamoto, T2
Fukagawa, T1
Katai, H3
Higuchi, K2
Boku, N11
Liao, W1
Huang, J3
Zhu, G1
Zhou, J1
Wen, F1
Zhang, P1
Zhou, K1
Wu, Q1
Wang, X4
Gou, H1
Li, Q3
Fujimoto, H1
Ito, S4
Kawaguchi, K2
Isobe, H1
Urayama, M1
Fuse, A1
Ota, K1
Yan, L1
Liu, H1
Li, H1
Han, X1
Cao, T1
Wang, C1
Li, G1
Kudo, R1
Manaka, D1
Ikeda, Y3
Ota, T1
Hamasu, S1
Konishi, S1
Nishitai, R1
Yang, PC1
Huang, KW1
Pua, U1
Kim, MD1
Li, SP1
Li, XY1
Liang, PC1
Shimizu, T2
Ishizuka, M1
Sakuraoka, Y1
Shiraki, T1
Abe, A1
Mori, S2
Iso, Y1
Takagi, K1
Aoki, T3
Jiang, Z1
Sun, Y1
Zhang, W1
Cui, C1
Yang, L2
Zhou, A1
Nishibeppu, K1
Komatsu, S1
Imamura, T1
Kiuchi, J1
Kishimoto, T2
Arita, T1
Kosuga, T1
Konishi, H2
Kubota, T3
Shiozaki, A1
Fujiwara, H1
Okamoto, K2
Otsuji, E2
Watanabe, H1
Hayashi, T10
Komori, K1
Hara, K2
Maezawa, Y1
Kano, K1
Shimoda, Y2
Fujikawa, H1
Aoyama, T4
Yamamoto, N3
Cho, H7
Ito, H1
Shiozawa, M1
Yukawa, N1
Morinaga, S1
Yoshikawa, T4
Rino, Y3
Masuda, M1
Ogata, T4
Oshima, T3
Urahigashi, A1
Fukunaga, H2
Sawami, H1
Hiraki, M2
Sawada, G1
Murakami, M4
Chihara, Y1
Yamamoto, M4
Kimura, H1
Morita, S15
Hokkoku, D2
Akamaru, Y3
Wada, N3
Wada, R3
Ikeshima, R2
Munakata, K3
Takiuchi, D3
Morimoto, O3
Ota, H7
Shibata, K3
Ohash, H1
Ando, K1
Tomimaru, Y2
Iwazawa, T1
Noguchi, K2
Nagase, H2
Ogino, T3
Hirota, M2
Oshima, K1
Tanida, T3
Noura, S2
Kawase, T2
Imamura, H9
Akagi, K1
Dono, K5
Deguchi, S1
Tendo, M1
Tani, N1
Sakimura, C1
Masuda, G1
Hori, T1
Nakata, B6
Ishikawa, T3
Hirakawa, K7
Sato, K4
Karasawa, H1
Kajiwara, T1
Suzuki, H2
Kohyama, A1
Watanabe, K2
Ohnuma, S1
Ishida, T1
Kamei, T2
Naitoh, T3
Unno, M4
Hayashi, Y1
Matsuo, Y2
Hamano, S1
Oba, A1
Ueda, G1
Omi, K1
Imafuji, H1
Saito, K1
Tsuboi, K1
Morimoto, M1
Ogawa, R1
Takahashi, H3
Takiguchi, S4
Kataoka, N1
Hiramatsu, S1
Yasuda, K1
Kashu, N1
Yoshitake, H1
Takami, T1
Tomita, M1
Shono, Y1
Makimoto, S1
Chuman, M1
Takahashi, Y6
Tokito, T1
Chino, S1
Ema, A1
Nakamura, K4
Kubo, H2
Naito, M1
Kondo, Y1
Nishi, Y1
Tamesa, T1
Saeki, S2
Nishida, Y1
Nabeya, M1
Tokunou, K1
Kawaoka, T1
Miyahara, M1
Sasaki, S1
Yamashita, Y2
Yamamoto, S3
Sato, T4
Nakamura, N1
Arai, S1
Tomi, Y1
Sanada, T1
Kuwabara, H3
Yoshida, T4
Goseki, N2
Koike, M2
Yoshida, R2
Nagata, M1
Hirosue, A1
Kawahara, K1
Nakamoto, M1
Hirayama, M1
Takahashi, N2
Matsuoka, Y1
Sakata, J1
Nakashima, H1
Arita, H1
Hiraki, A1
Shinohara, M1
Kikuchi, K1
Nakayama, H3
Kinoshita, S1
Higashida, M1
Kubota, H2
Kitagawa, S1
Iwamoto, R1
Ueno, M3
Mineta, S1
Okamoto, Y1
Watanabe, Y2
Okada, T3
Tsuruta, A1
Akiyama, T1
Fujiwara, Y6
Ueno, T1
Kobayashi, T2
Mizuno, S1
Matsuba, H1
Kanamori, M1
Maruyama, S1
Tamauchi, T1
Tohyama, T1
Sakamoto, K3
Tamura, K2
Nakamura, T3
Watanabe, J1
Wakisaka, H1
Takada, Y1
Ogawa, K2
Honda, M1
Akashi, Y1
Inagawa, S1
Kaneda, A1
Hori, S1
Owada, Y1
Ohara, Y1
Hisakura, K1
Enomoto, T1
Shimomura, O1
Takahashi, K8
Oda, T1
Xu, XJ1
Wang, ZM1
Shang, YP1
Jiang, SN1
Harada, H2
Yokoi, K1
Nishizawa, N1
Naruse, T1
Hirono, Y1
Kurebayashi, H1
Katayama, H1
Sawai, K1
Morikawa, M1
Koneri, K1
Tamaki, M1
Goi, T1
Kang, M1
Youn, HG1
An, JY2
Choi, MG2
Lee, JH2
Sohn, TS3
Bae, JM2
Kim, S3
Shimokawa, T4
Yamada, K1
Tanaka, H5
Takiguchi, Y2
Kishi, K2
Saito, H1
Hosomi, Y1
Kato, T4
Harada, D1
Otani, S1
Kasai, T1
Nakamura, Y3
Misumi, T2
Yamanaka, T4
Okamoto, H2
Obana, A1
Usui, S1
Koyama, M2
Koide, N1
Iwasaki, K1
Matsumura, T1
Sato, Y3
Kitamura, K2
Nomori, H1
Suwa, T1
Yamakoshi, Y1
Ohtani, H1
Nagamori, M1
Nomura, S1
Nakagawa, H1
Yoshii, M1
Tamura, T3
Toyokawa, T2
Muguruma, K3
Ohira, M3
Eguchi, S1
Noro, H1
Hirao, T1
Takayama, K1
Hara, S1
Yoshida, M1
Yoneda, K1
Ohashi, T1
Osawa, H1
Sakai, K1
Ide, Y2
Iwasaki, T1
Hatanaka, N1
Yamasaki, Y1
Yoshida, Y1
Okubo, K1
Arigami, T1
Matsushita, D1
Tanaka, T2
Tsuruda, Y1
Noda, M1
Sasaki, K2
Kurahara, H1
Ohtsuka, T1
Inoue, H3
Todaka, A2
Yamazaki, K5
Fushiki, K1
Shirasu, H1
Kawakami, T1
Tsushima, T3
Hamauchi, S2
Yokota, T2
Machida, N5
Fukutomi, A5
Onozawa, Y5
Andoh, A1
Yasui, H7
Morita, R1
Sawai, Y1
Kajiwara, M1
Asaeda, K1
Miyazaki, H1
Doi, T4
Inoue, K4
Dohi, O1
Yoshida, N1
Kamada, K1
Uchiyama, K1
Takagi, T2
Naito, Y1
Itoh, Y1
Li, B1
Shen, S1
You, S1
Zhang, G1
Gao, S1
Shi, X1
Wang, H1
Yin, X1
Xu, X1
Guo, S1
Jin, G1
Miki, M1
Takao, S1
Konishi, M4
Shigeoka, Y1
Miyashita, M1
Suwa, H1
Miyoshi, Y2
Hirokaga, K1
Okuno, T3
Yamagami, K1
Imamura, M1
Murase, K1
Yanai, A1
Tanino, H1
Natsuki, S1
Kato, Y3
Nishimura, S1
Taenaka, N2
Hirono, S1
Kawai, M1
Okada, KI1
Miyazawa, M1
Kitahata, Y1
Hayami, S1
Yamaue, H1
Tei, M1
Ohue, M2
Kitakaze, M1
Miyoshi, N1
Uemura, M3
Mizushima, T4
Murata, K3
Doki, Y9
Eguchi, H5
Nakazawa, N1
Sohda, M1
Ide, M1
Ubukata, Y1
Kuriyama, K1
Sano, A1
Sakai, M1
Yokobori, T1
Ogawa, H1
Oyama, T2
Shirabe, K1
Saeki, H1
Nishizawa, Y1
Haraguchi, N1
Kim, H2
Nakata, K1
Okamura, S1
Kudo, T2
Satoh, T3
Matsuda, C2
Nagakawa, Y1
Hosokawa, Y1
Sahara, Y1
Takishita, C1
Nakajima, T3
Hijikata, Y1
Kasuya, K1
Katsumata, K2
Tokuuye, K1
Tsuchida, A2
Takayoshi, K1
Kusaba, H2
Uenomachi, M1
Mitsugi, K2
Makiyama, C1
Makiyama, A1
Uchino, K1
Shirakawa, T1
Shibata, Y1
Shinohara, Y1
Inadomi, K1
Tsuchihashi, K1
Arita, S1
Ariyama, H2
Esaki, T5
Akashi, K2
Baba, E3
Das, K1
Taguri, M1
Sugimoto, N2
Nishikawa, K3
Yoshida, K11
Tan, P1
Tsuburaya, A9
Kawahara, T1
Shimozuma, K1
Shiroiwa, T1
Hagiwara, Y2
Uemura, Y3
Watanabe, T5
Taira, N1
Fukuda, T1
Ohashi, Y7
Mukai, H2
Hayashi, K3
Nagasaki, E1
Nakada, K1
Tamura, M1
Arakawa, Y1
Uwagawa, T2
Yano, S1
Okabayashi, T1
Shima, Y1
Iwata, J1
Sumiyoshi, T1
Sui, K1
Shimada, Y3
Iiyama, T1
Zhao, DB1
Chi, Y1
Tang, Y1
Li, N1
Wang, SL1
Song, YW1
Liu, YP1
Liu, WY1
Ren, H1
Zhang, T1
Wang, JY1
Chen, XS1
Fang, H1
Wang, WH1
Li, YX1
Jin, J1
Wei, J1
Dong, X1
Du, F1
Tang, S1
Wei, H1
Kawachi, S1
Shinoda, Y1
Kimura, M5
Usami, E2
Yoshimura, T3
Kim, SM3
Lee, J2
Sasako, M4
Kano, Y2
Takahari, D5
Chin, K5
Yamaguchi, K5
Tsuda, Y1
Shoji, Y1
Yasufuku, I1
Eto, K1
Ida, S2
Kumagai, K2
Nunobe, S3
Sano, T4
Nakachi, K1
Ikeda, M3
Shimada, K2
Okusaka, T2
Saiura, A1
Ishii, H1
Sugiyama, M1
Furuse, J1
Sakamoto, H1
Shimamura, T1
Ohta, T1
Yamada, D1
Iwagami, Y1
Asaoka, T1
Noda, T2
Kawamoto, K2
Gotoh, K1
Kobayashi, S4
Mori, M7
Miki, Y1
Kubo, N4
Sakurai, K1
Aoki, Y2
Ochiai, K1
Lim, S1
Aoki, D1
Kamiura, S1
Lin, H1
Katsumata, N2
Cha, SD1
Kim, JH4
Kim, BG1
Hirashima, Y1
Fujiwara, K1
Kim, YT1
Chung, HH1
Chang, TC1
Kamura, T1
Takizawa, K1
Takeuchi, M3
Kang, SB1
Shinkai, M2
Imano, M4
Chiba, Y2
Hiraki, Y2
Kato, H2
Iwama, M2
Shiraisi, O1
Yasuda, A2
Tsubaki, M2
Nishida, S2
Kimura, Y14
Yasuda, T5
Shiraishi, O1
Hanibuchi, M1
Kakiuchi, S1
Atagi, S1
Ogushi, F1
Shimizu, E1
Haku, T1
Toyoda, Y2
Azuma, M3
Kondo, M2
Kawano, H1
Otsuka, K1
Sakaguchi, S1
Nokihara, H2
Goto, H2
Nishioka, Y1
Terashima, M3
Misawa, K1
Hirao, M2
Oki, E4
Emi, Y6
Bando, H2
Kawashima, Y1
Fukunaga, T2
Gotoh, M4
Ishibashi, T1
Shitara, K5
Ryu, MH5
Kato, K4
Chung, HC4
Minashi, K2
Lee, KW1
Kang, WK5
Komatsu, Y6
Tsuda, M2
Hara, H2
Fumita, S1
Chen, LT1
Kang, YK5
Haga, T1
Fujimura, T2
Aiba, S1
Tsuchiya, T3
Matsumoto, K3
Miyazaki, T2
Yamaguchi, H3
Yamazaki, T1
Sano, I1
Fukuoka, J2
Yamasaki, N2
Nagayasu, T2
Muroya, T1
Wajima, N1
Yoshida, E1
Akaishi, T1
Umetsu, S1
Wakasa, Y2
Mitsuhashi, Y1
Umemura, K1
Ogasawara, H1
Hara, Y1
Hakamada, K2
Suzuki, T2
Tazawa, H1
Kojima, M2
Akabane, S1
Hadano, N1
Shimizu, W1
Ishiyama, K1
Onoe, T1
Sudo, T2
Shimizu, Y1
Hinoi, T1
Tashiro, H2
Yoshihara, T2
Hamabe, A1
Okada, K1
Oka, Y1
Kawanaka, S1
Taniguchi, S1
Adachi, S1
Yoshioka, S3
Ueshima, S1
Higaki, N1
Hayashida, H1
Nezu, R2
Tsuruta, S1
Kimura, N1
Ishido, K2
Kudo, D1
Sakuraba, S1
Sawano, T1
Suto, A1
Aoki, M1
Fukunari, H2
Kawai, Y1
Watanabe, A2
Umebayashi, Y1
Saito, T1
Alexey, A1
Ajioka, Y1
Azama, T1
Kitada, M1
Noma, T1
Takahashi, T6
Miyazaki, Y2
Kurokawa, Y4
Tanaka, K1
Makino, T3
Nakajima, K3
Yamasaki, M1
Takahashi, R2
Nagino, M3
Kawada, J1
Nishino, M1
Hata, M1
Tanizaki, K2
Hoshino, H1
Okano, M1
Nagai, K1
Kim, Y1
Okuyama, M1
Tsujinaka, T3
Imamoto, H3
Xu, B1
Liu, Y1
Lu, P1
Ba, Y1
Wu, L1
Bai, Y1
Zhang, S1
Feng, J1
Cheng, Y1
Li, J1
Wen, L1
Yuan, X1
Ma, C1
Hu, C1
Fan, Q1
Wakasaki, T1
Yasumatsu, R1
Uchi, R1
Taura, M1
Matsuo, M1
Komune, N1
Nakagawa, T1
Mitani, S1
Kadowaki, S2
Hasegawa, H1
Wakatsuki, T1
Tajika, M3
Muro, K4
Kohira, Y1
Ishibashi, Y1
Egawa, H1
Yube, Y1
Kaji, S1
Kanda, S1
Oka, S1
Kajiyama, Y1
Ito, T3
Honma, Y1
Hirano, H1
Shoji, H2
Okita, N1
Iwasa, S1
Ariake, K1
Motoi, F3
Mizuma, M1
Ohtsuka, H2
Nakagawa, K6
Hata, T3
Mitachi, K1
Seki-Soda, M1
Koshi, H1
Yokoo, S1
Takatori, E1
Shoji, T1
Suga, Y1
Niinuma, H1
Miura, Y1
Kaido, Y1
Takada, A1
Kagabu, M1
Takeuchi, S1
Sugiyama, T2
Okada, H1
Taira, K1
Tokunaga, S1
Daga, H1
Miyamoto, N1
Nishijima, M1
Sumitani, M1
Syoji, S1
Takeda, K3
Nishio, M1
Murakami, H1
Ohyanagi, F1
Kozuka, T1
Ishikura, S1
Naito, T1
Kaira, K1
Horiike, A1
Nishimura, T2
Fukunaga, M1
Fukuzaki, T1
Ohnishi, T2
Tanaka, N1
Takemasa, I2
Yamamoto, H7
Sekimoto, M1
Yamashita, H1
Okuma, K1
Shiraishi, K1
Ohtomo, K1
Suzuki, Y1
Ogiya, R1
Oshitanai, R1
Terao, M1
Terada, M1
Morioka, T1
Tsuda, B1
Niikura, N1
Okamura, T2
Saito, Y1
Tokuda, Y1
Yunokawa, M1
Kodaira, M1
Yonemori, K1
Shimizu, C1
Ando, M1
Wada, T1
Kunisaki, C4
Hasegawa, S2
Takagawa, R2
Momiyama, M1
Kosaka, T2
Makino, H2
Ono, HA2
Akiyama, H2
Endo, I2
Akutsu, Y1
Kono, T1
Uesato, M1
Hoshino, I1
Narushima, K1
Hanaoka, T1
Tochigi, T1
Semba, Y1
Qin, W1
Matsubara, H1
Hamaguchi, T1
Yoshimura, K3
Fuse, N3
Goto, M2
Tanigawa, N1
Shirao, K2
Fujitani, K4
Tamura, S2
Matsuyama, J2
Iijima, S4
Kobayashi, K2
Furukawa, H6
Yutani, S1
Komatsu, N1
Yoshitomi, M1
Matsueda, S1
Yonemoto, K1
Mine, T2
Noguchi, M1
Ishihara, Y1
Yamada, A1
Itoh, K1
Sasada, T1
Otsuka, H1
Fujii, T2
Toh, U1
Iwakuma, N1
Mishima, M1
Takenaka, M1
Kakuma, T1
Shirouzu, K1
Ishida, K1
Fujishima, F1
Ottomo, S1
Oikawa, M1
Shimamura, H1
Takemura, S1
Ono, F1
Akada, M1
Katayose, Y2
Egawa, S2
Takiuchi, H5
Morimoto, T2
Maruyama, K1
Otsuji, T1
Omura, T1
Nagata, T1
Okumura, T1
Yamagishi, F1
Tajika, S1
Nakajima, S1
Kawabe, A1
Tsukada, K1
Naitoh, H1
Murata, S1
Kobayashi, H2
Tani, T1
Canbay, E1
Mizumoto, A1
Ichinose, M1
Ishibashi, H1
Sako, S1
Hirano, M1
Takao, N1
Yonemura, Y2
Koizumi, W3
Kim, YH1
Fujii, M7
Kim, HK1
Lee, KH5
Hara, T1
Cho, JY1
Hosaka, H1
Tsuji, A5
Takagane, A2
Inokuchi, M1
Tanabe, K6
Ogura, M1
Morizane, C1
Hiraoka, N1
Kondo, S2
Ueno, H2
Ohno, I1
Shimizu, S2
Mitsunaga, S1
Nakamura, A2
Itasaka, S1
Takaori, K1
Kawaguchi, Y1
Shibuya, K1
Yoshimura, M1
Mizowaki, T1
Uemoto, S2
Hiraoka, M1
Hu, JB1
Sun, XN1
Gu, BX1
Wang, Q2
Hu, WX1
Wang, M1
Wu, M1
Wang, W1
Wang, Y2
Higashino, M2
Kawata, R1
Lee, K1
Nishikawa, S1
Ichihara, S1
Uesugi, Y1
Cabalag, CS1
Chan, ST1
Kaneko, Y1
Duong, CP1
Takashima, T3
Nakayama, T1
Yoshidome, K1
Kawajiri, H1
Kamigaki, S1
Tsurutani, J1
Arai, T1
Komoike, Y1
Masuda, N2
Miyauchi, K1
Sakamoto, J12
Taguchi, T4
Higashi, D1
Egawa, Y1
Hirano, Y1
Hirano, K2
Miyake, T1
Uwatoko, S1
Abe, S2
Mikami, K1
Futami, K1
Maekawa, T2
Inoue, R1
Miyazaki, M1
Peng, PJ1
Cheng, H1
Ou, XQ1
Zeng, LJ1
Wu, X1
Liu, YM1
Lin, Z1
Tang, YN1
Wang, SY1
Zhang, HY1
Chen, ZB1
Emoto, S1
Kitayama, J1
Ishigami, H1
Lee, SJ1
Park, SH1
Park, JO1
Lim, DH1
Park, YS1
Lim, HY1
Sueda, T2
Sakai, D2
Nishimura, J2
Ezoe, S1
Abe, K1
Okui, N1
Hata, D1
Shiba, H1
Futagawa, Y1
Aiba, K1
Yanaga, K3
Nogami, N2
Takigawa, N1
Hotta, K2
Segawa, Y2
Kozuki, T1
Oze, I1
Kishino, D1
Aoe, K1
Ueoka, H1
Kuyama, S1
Harita, S1
Hosokawa, S1
Gemba, K1
Shibayama, T1
Tabata, M1
Takemoto, M1
Kanazawa, S1
Tanimoto, M1
Kiura, K1
Saito, M1
Kiyozaki, H1
Takata, O1
Suzuki, K1
Rikiyama, T2
Sasaki, T3
Isayama, H2
Nakai, Y2
Ito, Y4
Yasuda, I1
Toda, N1
Yagioka, H2
Matsubara, S2
Hanada, K1
Maguchi, H1
Kamada, H1
Hasebe, O1
Mukai, T1
Okabe, Y1
Maetani, I1
Koike, K1
Kim, HS3
Kim, HY1
Zang, DY3
Oh, HS1
Jeon, JY1
Cho, JW1
Park, CK1
Kim, MJ1
Ha, HI1
Han, B1
Song, H1
Kwon, JH1
Choi, DR1
Jung, JY1
Zhong, DT1
Wu, RP1
Wang, XL1
Huang, XB1
Lin, MX1
Lan, YQ1
Chen, Q1
Tsukahara, K1
Kubota, A1
Hasegawa, Y3
Takemura, H1
Terada, T1
Nagahara, K1
Nakatani, H1
Yoshino, K1
Higaki, Y1
Iwae, S1
Beppu, T1
Hanamure, Y1
Tomita, K2
Kohno, N2
Kawabata, K1
Fukushima, M5
Teramukai, S4
Hishida, T1
Tsuboi, M1
Shukuya, T1
Takamochi, K1
Sakurai, H1
Yoh, K1
Kunitoh, H1
Kaneko, J1
Isogai, J1
Hasegawa, K1
Matsui, T3
Aoyagi, H1
Maejima, S1
Kabashima, A2
Kitagawa, D1
Kondo, N2
Teramoto, S2
Saito, G1
Funahashi, T1
Adachi, E1
Yamamoto, D1
Iwase, S2
Tsubota, Y1
Ariyoshi, K1
Kawaguchi, T1
Miyaji, T1
Sueoka, N1
Yamamoto, C1
Odagiri, H1
Nagumo, Y1
Uehara, K2
Maeda, A2
Sakamoto, E2
Hiramatsu, K2
Takeuchi, E2
Tojima, Y2
Yatsuya, H1
Qiu, M1
Peng, XC1
Bi, F1
Xu, F1
Li, ZP1
Shen, YL1
Liu, JY1
Zhao, YQ1
Cao, D1
Gou, HF1
Yang, Y2
Chen, Y2
Yi, C1
Kanda, M1
Murotani, K1
Kobayashi, D2
Tanaka, C1
Yamada, S2
Nakayama, G1
Sugimoto, H1
Fujiwara, M1
Park, YI1
Hyodo, I2
Nam, BH1
Yoo, C1
Ryoo, BY2
Song, EK2
Cho, SH4
Yang, SH2
Shin, DB2
Park, SR2
Shinozaki, K1
Takano, T1
Tanigawa, T3
Matoda, M1
Yamamoto, A1
Nomura, H1
Okamoto, S1
Kondo, E1
Omatsu, K1
Takeshima, N1
Nishina, T2
Hamamoto, Y1
Kawai, H1
Nakayama, N2
Amagai, K1
Mizusawa, J1
Ohtsu, A3
Sakaguchi, Y2
Kinjo, N1
Yamaguchi, S1
Egashira, A2
Minami, K1
Morita, M2
Toh, Y1
Nakanishi, K2
Mochizuki, Y2
Ishigure, K1
Kojima, H2
Ishiyama, A1
Fujitake, S1
Shikano, T1
Okabe, H2
Ueda, S2
Zaima, M1
Tokuka, A1
Ota, S1
Kinjo, Y1
Sakai, Y3
Hironaka, S4
Moriwaki, T1
Nakajima, TE1
Sekikawa, T1
Matsumoto, S5
Baba, H5
Okubo, S1
Yamazaki, M1
Shim, HJ1
Kim, KR1
Hwang, JE1
Bae, WK1
Ryu, SY1
Park, YK1
Nam, TK1
Chung, IJ2
Murata, A1
Maeda, K2
Ikejiri, K1
Munemoto, Y1
Kotake, M1
Suenaga, T1
Matsuda, H1
Kakeji, Y4
Hamada, C2
Saji, S7
Maehara, Y5
Soh, J1
Okumura, N1
Nakata, M1
Nakamura, H2
Fukuda, M1
Kataoka, M1
Kajiwara, S1
Sano, Y1
Aoe, M1
Kataoka, K1
Matsuo, K3
Toyooka, S1
Date, H1
Tomioku, M1
Yazawa, N1
Furukawa, D1
Izumi, H1
Mashiko, T1
Ozawa, S1
Sadahiro, S1
Yasuda, S1
Hirabayashi, K1
Nakagohri, T1
Mabuchi, S1
Yokoi, E1
Owa, T1
Kozasa, K1
Yamashita, M1
Kobayashi, E1
Tomimatsu, T1
Yoki, T1
Tsutui, T1
Kimura, T2
Taki, T1
Hoya, Y1
Nakayoshi, T1
Okamoto, T1
Sekine, H1
Mitsumori, N3
Egashira, S1
Kajihara, I1
Kanemaru, H1
Uemura-Kiyohara, M1
Yamada-Kanazawa, S1
Nakahara, S1
Nagamoto, E1
Fukushima, S1
Jinnin, M1
Inoue, Y3
Ihn, H1
Yeo, W1
Lam, KO1
Law, AL1
Lee, CC1
Chiang, CL1
Au, KH1
Mo, FK1
So, TH1
Lam, KC1
Ng, WT1
Li, L1
Hoshino, S1
Sugano, T1
Kitamura, T1
Furukawa, M1
Aragane, K1
Lee, JL3
Kang, HJ3
Kim, JG2
Chang, HM3
Kim, TW3
Baek, JH3
Min, YJ1
Matsumoto, M1
Udagawa, I1
Yasutomi, J1
Kusashio, K1
Kasagawa, T1
Tonooka, T1
Tashima, Y1
Irabu, S1
Nobumoto, D1
Suzuki, M4
Fukao, K1
Osaki, Y2
Tokudome, N1
Sugihara, T1
Takahashi, S3
Iwase, T1
Hatake, K1
Lee, JJ1
Kim, SY1
Song, HS2
Hong, YS3
Choi, IS1
Lee, YY1
Woo, IS1
Choi, JH1
Nakashima, K1
Taku, K3
Kojima, T3
Seol, YM1
Song, MK1
Choi, YJ1
Kim, GH1
Shin, HJ1
Song, GA1
Chung, JS1
Cho, GJ1
Uemura, T1
Fujimitsu, Y1
Kure, N1
Tokunaga, N1
Itaba, S1
Yoshinaga, S1
Murao, H1
Akiho, H1
Nagai, E1
Goto, A2
Takayanagi, R1
Ono, A1
Yoshino, T2
Yamashita, T4
Shinden, S1
Watabe, T1
Shiotani, A1
Sadanaga, N1
Takahashi, I4
Yashima, Y1
Kogure, H1
Arizumi, T1
Togawa, O1
Sasahira, N1
Tsujino, T1
Tada, M1
Kawabe, T1
Omata, M1
Suzuki, S6
Ishikawa, K2
Yamada, Y1
Akasaka, O1
Miwa, H1
Ando, T1
Koh, R1
Kasama, M1
Matsueda, R1
Anan, H1
Ishii, Y1
Takayama, T3
Asai, S1
Nishijima, W1
Tsukuda, M2
Ishitoya, J1
Yamane, H1
Homma, A1
Tomita, T1
Sugiura, Y1
Takeuchi, K2
Kakizaki, T1
Kaseda, S1
Kadono, K1
Park, T1
Nakano, D2
Matsumoto, H3
Iwasaki, Y5
Iwanaga, T2
Fujiwara, N1
Tamai, S1
Matsumura, H1
Naitou, A1
Hashimoto, K1
Yokoyama, S1
Fukushima, Y1
Nishishou, I1
Nomura, T2
Sasaki, Y2
Taniguchi, M1
Ookubo, K1
Ootsuka, M1
Akitake, H1
Hama, N1
Kashiwazaki, M1
Tsujie, M2
Ebisui, C2
Fujimoto, T2
Igarashi, Y1
Yamanaka, C1
Komori, T1
Matsumoto, T1
Takachi, K1
Nishioka, K1
Ami, K1
Nagahama, T1
Ohara, T1
Ganno, H1
Hataji, K1
Kurokawa, T1
Fukuda, A1
Andou, M1
Tei, S1
Arai, K4
Tomokuni, A1
Marubashi, S4
Nagano, H5
Takeda, Y3
Tanemura, M2
Kitagawa, T2
Monden, M5
Machida, H1
Tominaga, K1
Yano, H2
Nobuhara, Y1
Matuoka, T1
Yo, T1
Yokoo, H1
Kamiyama, T1
Tahara, M2
Fukumori, D1
Kamachi, H1
Matsushita, M1
Todo, S2
Jingu, K1
Ariga, H2
Kaneta, T2
Takai, Y1
Katja, L1
Narazaki, K1
Metoki, T1
Fujimoto, K2
Umezawa, R1
Ogawa, Y1
Nemoto, K2
Koto, M1
Mitsuya, M1
Matsufuji, N1
Kim, JY1
Do, YR1
Park, KU1
Chae, YS1
Kim, MK1
Ryoo, HM1
Bae, SH1
Hozumi, Y1
Murakami, S2
Mitsuyama, S1
Ohmura, T1
Yajima, T1
Tokumoto, N1
Ohdan, H1
Araki, K2
Okano, S1
Kiyota, N1
Zenda, S1
Kawashima, M1
Hayashi, R1
Minami, H2
Oh, SY1
Kwon, HC1
Jeong, SH1
Joo, YT1
Lee, YJ1
Kang, MH1
Go, SI1
Lee, GW1
Kim, Hg1
Kang, JH1
Takahashi, M4
Fujii, S1
Kimura, J1
Kameda, K1
Kito, F1
Kanai, M2
Tsumura, T1
Asada, M1
Suzuki, C1
Niimi, M1
Nitta, T1
Yasuchika, K1
Taura, K1
Mori, Y2
Hamada, A1
Inoue, N1
Tada, S1
Yanagihara, K1
Yazumi, S1
Chiba, T1
Ikai, I1
Hatano, E2
Ueda, Y2
Yamagishi, H2
Ichikawa, D2
Morii, J2
Koizumi, K2
Kakihara, N2
Shimotsuma, M2
Taniguchi, F1
Aragane, H1
Nishi, H1
Itokawa, Y1
Naito, S1
Eto, M1
Shinohara, N1
Tomita, Y1
Fujisawa, M1
Namiki, M1
Nishikido, M1
Usami, M1
Tsukamoto, T1
Akaza, H1
Katsuno, M1
Watanabe, N2
Sugio, Y1
Tachibana, S1
Tani, Y1
Sato, N1
Zusho, H1
Sunaga, T1
Harada, N2
Kakita, T1
Funayama, Y1
Tokumura, H1
Toshima, T1
Fukuyama, S1
Musya, H1
Matsumura, N1
Sasaki, H1
Yasumoto, A1
Kogashiwa, Y1
Yamauchi, K1
Nagafuji, H1
Matsuda, T1
Tsubosaka, T1
Karaho, T1
Maruyama, T1
Seto, T1
Ichinose, Y1
Shinkai, T1
Minato, K1
Seki, N1
Eguchi, K1
Nishikawa, M1
Takeda, M1
Okamoto, I1
Hirabayashi, N4
Kitano, M2
Morikita, T1
Fujishima, H1
Nakano, S1
Maejima, K1
Tokunaga, A2
Kiyama, T1
Kanno, H1
Bou, H1
Uchida, E1
Shimabukuro, R1
Shiraishi, T1
Nishizaki, T2
Endo, W1
Fujie, Y1
Shimizu, K1
Yoshioka, A1
Hojou, S1
Maeura, Y1
Nakamura, M3
Morimoto, J1
Amano, R1
Noda, E1
Inoue, T1
Yamada, N1
Yashiro, M1
Onoda, N2
Sawada, T1
Taniguchi, H3
Miyazaki, S1
Kim, C1
Danno, K1
Kagara, N1
Kanoh, T1
Tohno, T1
Nakano, Y1
Kagawa, K1
Monden, T1
Imaoka, S1
Kanamura, T1
Kojima, Y1
Fujita, S2
Ikeda, N1
Wada, H4
Umeshita, H1
Choi, YH2
Lee, SS1
Narahara, H2
Iishi, H1
Sakata, Y3
Mitachi, Y2
Kamano, T1
Oikawa, K1
Kambe, M1
Shirasaka, T2
Tanaka, Y2
Oda, H1
Tajima, Y1
Sakurai, J1
Wakasugi, T1
Tatebe, S1
Kitajima, M3
Sakuma, T1
Deguchi, R1
Takashimizu, S1
Ogasawara, F1
Numata, M1
Ohtani, Y1
Sato, S1
Iwata, Y1
Yuki, S1
Sogabe, S1
Fukushima, H1
Iwanaga, I1
Kudo, M1
Tateyama, M1
Meguro, T1
Uebayashi, M1
Saga, A1
Asaka, M1
Satoh, S2
Ozaki, N1
Sakabayashi, S1
Yamada, H1
Horie, A1
Iketani, S1
Kanai, I1
Nakatani, Y1
Hamada, Y1
Tanabe, S1
Nishimura, K1
Takagi, S1
Ae, T1
Nakatani, K1
Naruke, A1
Katada, C1
Yakabe, T1
Noshiro, H1
Ikeda, O1
Miyoshi, A1
Kitajima, Y1
Asahina, H1
Sekine, I1
Horinouchi, H1
Takiguchi, N1
Takagi, M1
Tokunaga, Y1
Fukushima, R1
Munakata, Y1
Sekishita, Y1
Mikayama, Y1
Kodama, Y1
Ajiki, T1
Ioka, T1
Murakami, Y2
Uemura, K1
Hashimoto, Y2
Nakashima, A1
Sakabe, R1
Nakagawa, N1
Nomiya, T1
Kuroda, Y1
Ichikawa, M1
Ota, I1
Takai, K1
Kenjo, M1
Mizota, A1
Kondo, C2
Ura, T2
Tagawa, T1
Akamine, S1
Hisano, H1
Taniguchi, Y1
Kitamura, Y1
Masuda, K1
Yamamoto, K1
Yoshida, H2
Onogawa, T1
Sawaki, A2
Niwa, Y1
Hamai, Y2
Emi, M1
Kushitani, K1
Okada, M1
Kim, HR1
Kim, GM1
Koh, YW1
Kim, SH1
Choi, EC1
Hong, YK1
Sung, JH1
Cho, BC2
Matsunaga, M1
Onishi, H1
Ishida, M1
Miwa, K1
Sunakawa, Y1
Noguchi, T1
Narabayashi, M1
Oh, SC1
Kim, JS1
Nam, SH1
Kim, BS1
Yim, CY1
Jeung, HC2
Wakisaka, N1
Endo, K1
Murono, S1
Yoshizaki, T1
Sakaguchi, K1
Ebata, T1
Cui, Y1
Yu, Y1
Feng, Y1
Liu, T1
Kaneoka, Y1
Teramachi, H1
Shigeyasu, K1
Kagawa, S1
Uno, F1
Nishizaki, M1
Kishimoto, H1
Gochi, A1
Takahata, T1
Nonaka, Y1
Ninomiya, M2
Fujiwara, T1
Yano, T1
Ono, H2
Sato, M1
Nishino, H1
Shinozaki, T1
Ichimura, K1
Nakai, S1
Morimoto, Y1
Kurihara, Y1
Sakurai, M1
Konishi, K1
Kobayashi, O1
Sairenji, M1
Motohashi, H1
Imada, T3
Kikkawa, N2
Naoi, Y2
Kurokawa, E2
Ohta, K2
Toge, T7
Nishiyama, M4
Honma, S2
Hatanaka, F1
Matsuo, S1
Aratake, Y1
Uchimura, K1
Yokota, M1
Sumii, T1
Iguchi, H1
Funakoshi, A1
Tamura, H1
Kurihara, H1
Kitago, M1
Ogihara, T1
Nimura, H2
Tsukagoshi, S1
Nakajima, M1
Atomi, Y1
Kusano, M1
Yoshiyuki, T1
Oeda, M1
Takiyama, W2
Nagamine, I1
Ohara, M1
Oshita, A1
Satou, Y1
Kirihara, Y1
Mukaida, H1
Hisamatu, K1
Matsuura, N1
Akagi, Y1
Ito, K1
Yamamura, Y2
Tanemura, H1
Oshita, H1
Miyashita, K1
Saeki, T1
Takashima, S2
Sano, M2
Horikoshi, N2
Miura, S1
Morimoto, K2
Makari, Y1
Yano, M2
Kawabata, Y1
Kusumoto, C1
Miyamoto, K1
Takeuchi, T2
Mai, M2
Tanigawara, Y1
Takeo, Y1
Tanaka, S1
Hanyu, F1
Nomura, M1
Katsura, H1
Sakao, J1
Yokotani, H1
Souda, S1
Souma, I1
Hayashi, N1
Fukuchi, N1
Izawa, H1
Sakita, I1
Hasuike, Y1
Miyata, H1
Sakon, M1
Yamamoto, T1
Damdinsuren, B2
Miyamoto, A2
Umeshita, K2
Nakamori, S1
Johira, H1
Yunoki, S1
Kawata, N1
Hachisuka, Y1
Uomoto, M1
Hatano, H1
Sanada, E1
Watanabe, R1
Ohmori, K1
Miyata, N1
Okita, K1
Ojima, Y1
Yamamura, S1
Matsusaka, T1
Morishita, Y1
Kasakura, Y1
Yamagata, M1
Kochi, M2
Ukon, K2
Shimoyama, S1
Imamura, K1
Mafune, K1
Kaminishi, M1
Takenaka, A1
Kurioka, H1
Kanda, T1
Yajima, K1
Banba, T1
Tanabe, T1
Kosugi, S1
Hatakeyama, K1
Tokunaga, E1
Ushiro, S1
Shintani, S1
Hino, S1
Nakashiro, K1
Hamakawa, H1
Takakura, N1
Sunagozaka, H1
Kagaya, T1
Kaneko, S1
Wada, Y1
Kashimura, H1
Takayama, S1
Kashiwagi, H1
Ohshima, T2
Yamada, R2
Hatori, S2
Yamazaki, Y1
Suda, T1
Takanashi, Y1
Otsuka, Y1
Rha, SY1
Yoo, NC1
Roh, JK1
Roh, WJ1
Ahn, JB1
Mochiki, E1
Ohno, T1
Kamiyama, Y1
Aihara, R1
Haga, N1
Ojima, H1
Nakamura, J1
Ohsawa, H1
Nakabayashi, T1
Asao, T1
Kuwano, H1
Uchida, K1
Kuramochi, H1
Nakajima, G1
Ishiwata, R2
Nagai, Y2
Sohn, HJ1
Lee, JS1
Yamamoto, Y1
Kida, A1
Kono, N1
Sugita, M2
Kanamori, N1
Wakabayashi, K1
Sou, K1
Tokita, H1
Kato, F1
Yamamoto, J1
Okuda, N1
Yagi, Y1
Ichikawa, K1
Yamaoka, T1
Katou, T1
Sakuramoto, S1
Nashimoto, A1
Kurita, A1
Mizuno, N1
Hoki, N1
Ishikawa, H1
Yamao, K1
Arita, A1
Fujimoto, M1
Mochizuki, K1
Watanabe, F1
Iwagami, S1
Yasutome, M1
Egawa, T1
Nagashima, A1
Doi, M1
Hayashi, S1
Sekine, K1
Shimizu, M1
Yoshii, H1
Ishida, H1
Alsamarai, S1
Zergebel, C1
Furuie, T1
Urrea, PD1
Saif, MW1
Inada, S1
Tomidokoro, T1
Hatano, T1
Nishimura, A1
Kawauchi, Y1
Nikkuni, K1
Yanagi, M1
Nakadaira, K1
Kurosaki, I1
Ueki, H1
Aoyama, H1
Ota, J1
Noguchi, S1
Nishimoto, N1
Kagawa, Y1
Kim, R1
Hirai, T1
Inaba, Y1
Watabe, S1
Ohe, S1
Kamio, Y1
Chiba, M1

Clinical Trials (35)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II, Single-center, Single-arm, Open-label Study of Nanoparticle Albumin-bound-paclitaxel (Nab-PTX) Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer[NCT04781413]Phase 1/Phase 238 participants (Anticipated)Interventional2021-03-01Recruiting
Infusional Fluorouracil and Weekly Docetaxel as First-line Therapy for Gastric Cancer With Bone Marrow Metastasis and Disseminated Intravascular Coagulation: a Multi-center, Phase II Trail[NCT04547153]Phase 224 participants (Actual)Interventional2021-01-15Completed
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)[NCT00152217]Phase 31,000 participants (Anticipated)Interventional2001-09-30Completed
A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tirelizumab in First-line Treatment of PDL1 CPS < 5 Advanced Gastroesophageal Adenocarcinoma[NCT05299476]Phase 230 participants (Anticipated)Interventional2022-04-16Recruiting
ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer[NCT02746796]Phase 2/Phase 3680 participants (Anticipated)Interventional2016-03-31Completed
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study[NCT02319187]Phase 3240 participants (Anticipated)Interventional2014-12-31Recruiting
Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986]Phase 246 participants (Anticipated)Interventional2015-03-31Recruiting
A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer[NCT00287768]Phase 3628 participants (Anticipated)Interventional2006-03-31Completed
Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study[NCT00336947]Phase 3500 participants (Anticipated)Interventional2006-04-30Active, not recruiting
Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074]Phase 248 participants (Anticipated)Interventional2016-07-22Recruiting
Phase III Trial of 3-weekly vs. 5-weekly Schedule of S-1 Plus Cisplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer.[NCT00915382]Phase 3625 participants (Actual)Interventional2009-01-31Completed
Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359]Phase 3111 participants (Actual)Interventional2014-02-28Completed
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552]Phase 3870 participants (Anticipated)Interventional2013-08-19Recruiting
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449]Phase 3338 participants (Actual)Interventional2012-12-31Completed
Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641]Phase 2100 participants (Anticipated)Interventional2019-01-28Recruiting
Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291]Phase 230 participants (Anticipated)Interventional2013-12-31Not yet recruiting
PhaseⅡSingle-center, Open-label, Exploratory Clinical Study of Apatinib in Combination With S1 for the Patients With Advanced Non-squamous Head and Neck Cancer[NCT02943252]Phase 230 participants (Anticipated)Interventional2016-10-31Recruiting
The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study[NCT05351398]54 participants (Anticipated)Observational2022-04-30Not yet recruiting
Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703]Phase 238 participants (Actual)Interventional2005-08-31Completed
Phase II Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Advanced Gastric Cancer[NCT00088816]Phase 250 participants (Anticipated)Interventional2003-04-30Active, not recruiting
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916]Phase 242 participants (Actual)Interventional2015-07-31Completed
A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407]Phase 127 participants (Actual)Interventional2010-11-30Completed
A Phase II Study of Docetaxel, Oxaliplatin and S-1 (DOS) in Patients With Advanced Gastric Cancer[NCT00525005]Phase 244 participants (Actual)Interventional2007-08-31Completed
A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618]Phase 241 participants (Actual)Interventional2014-07-05Completed
[NCT01946061]Phase 23 participants (Actual)Interventional2015-05-31Terminated (stopped due to This study was stopped because of difficulties of supplying the drug.)
Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients[NCT00687843]Phase 3480 participants (Anticipated)Interventional2008-06-30Active, not recruiting
Prospective Multicenter Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer[NCT01456598]1,050 participants (Actual)Interventional2011-11-21Completed
Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer[NCT02572050]Phase 287 participants (Anticipated)Interventional2015-10-31Recruiting
A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection[NCT03601988]Phase 3408 participants (Anticipated)Interventional2018-07-28Recruiting
Apatinib Plus S-1 for Advanced Gastric Cancer Refractory to Oxaliplatin Plus Capecitabine Combination Therapy: A Single-arm, Phase-2, Home-based Trial[NCT04338438]Phase 237 participants (Actual)Interventional2015-05-01Completed
A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery Using a Phase 3 [NCT03403296]640 participants (Actual)Observational2016-07-13Completed
Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261]Phase 3556 participants (Anticipated)Interventional2018-10-01Not yet recruiting
Multicenter Study on Comparison of Long-term Outcome Between Laparoscopic and Open Distal Subtotal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer[NCT01609309]Phase 31,056 participants (Anticipated)Interventional2012-09-30Active, not recruiting
Evaluation of Inflammatory Markers in Laparoscopic and Abdominal Hysterectomies: A Retrospective Study in Kocaeli, Northwest Turkey[NCT04184765]212 participants (Actual)Observational2018-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

10 reviews available for oxonic acid and Local Neoplasm Recurrence

ArticleYear
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
    World journal of surgical oncology, 2020, May-28, Volume: 18, Issue:1

    Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combi

2020
A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015, Volume: 18, Issue:1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Int

2015
Hypomanic episode during recurrent gastric cancer treatment: report of a rare case and literature review.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:10

    Topics: Aged; Antineoplastic Agents; Bipolar Disorder; Cisplatin; Drug Combinations; Female; Humans; Neoplas

2012
[Weekly administration of paclitaxel with a short course of premedication for advanced or recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2003
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2003
[Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:12

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Ph

2004
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Do

2004
[Combination chemotherapy of TS-1 and docetaxel on advanced and recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combin

2004
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli

2006
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2007

Trials

106 trials available for oxonic acid and Local Neoplasm Recurrence

ArticleYear
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
    Future oncology (London, England), 2022, Volume: 18, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplas

2022
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
    Expert review of pharmacoeconomics & outcomes research, 2020, Volume: 20, Issue:1

    Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Di

2020
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
    Cancer medicine, 2021, Volume: 10, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora

2021
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
    BMC cancer, 2021, Aug-23, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop

2021
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteri

2017
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
    Cancer letters, 2018, 01-01, Volume: 412

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female

2018
Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer.
    Oncology, 2018, Volume: 94, Issue:2

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Drug Combinations; Female; Fl

2018
S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
    British journal of cancer, 2018, 02-06, Volume: 118, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Dr

2018
Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    BMC cancer, 2018, 04-20, Volume: 18, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Mo

2018
Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
    British journal of cancer, 2018, Volume: 119, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi

2018
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
    Anticancer research, 2018, Volume: 38, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; H

2018
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Lung cancer (Amsterdam, Netherlands), 2018, Volume: 125

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C

2018
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
    Annals of surgical oncology, 2019, Volume: 26, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy,

2019
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 02-01, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C

2019
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 02-01, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C

2019
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 02-01, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C

2019
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 02-01, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C

2019
Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer.
    General thoracic and cardiovascular surgery, 2019, Volume: 67, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora

2019
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
    Cancer communications (London, England), 2019, 04-02, Volume: 39, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas

2019
Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
    Clinical lung cancer, 2013, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemothera

2013
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2013
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D

2013
Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2014
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
    Oncology reports, 2013, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cis

2013
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
    Breast cancer (Tokyo, Japan), 2015, Volume: 22, Issue:4

    Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop

2015
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
    Annals of surgical oncology, 2013, Volume: 20, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit

2013
Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).
    Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule;

2014
Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Collagen; Docetaxel;

2014
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2014
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2015
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
    Lung cancer (Amsterdam, Netherlands), 2015, Volume: 87, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora

2015
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
    World journal of gastroenterology, 2014, Dec-28, Volume: 20, Issue:48

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; De

2014
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2015
Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC).
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Head and N

2015
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine;

2015
Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-

2015
Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemor

2015
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

2015
Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
    Archives of gynecology and obstetrics, 2016, Volume: 293, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans;

2016
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin

2016
Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
    International journal of clinical oncology, 2016, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2016
A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
    Journal of surgical oncology, 2016, Volume: 113, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise

2016
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Fre

2016
A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem

2016
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2016
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2016
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca

2016
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Comb

2009
Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
    Anticancer research, 2009, Volume: 29, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2009
Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Oncology, 2009, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D

2009
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Follow-Up St

2010
Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2010
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Co

2011
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Ne

2010
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Rel

2011
A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2012
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva

2011
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine;

2011
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2010, Volume: 13, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Interval

2010
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Dihydrouracil Dehydrogenase (NADP); Di

2010
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
    Chemotherapy, 2010, Volume: 56, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin

2010
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2011
Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2011
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2010, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime

2010
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2011
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2011, Volume: 14, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb

2011
Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).
    Oncology, 2010, Volume: 79, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug

2010
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
    Anti-cancer drugs, 2011, Volume: 22, Issue:6

    Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; An

2011
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C

2011
Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2012, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D

2012
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Admi

2012
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2012, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise

2012
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid

2012
A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer.
    International journal of clinical oncology, 2013, Volume: 18, Issue:2

    Topics: Aged; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Mi

2013
A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Clinical lung cancer, 2012, Volume: 13, Issue:6

    Topics: Administration, Oral; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C

2012
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2012
Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
    Annals of surgical oncology, 2013, Volume: 20, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy,

2013
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydroge

2013
Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; H

2013
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2003, Volume: 6 Suppl 1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla

2003
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2003, Volume: 6 Suppl 1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cisplatin; Dose-Response Relationsh

2003
[Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul

2003
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Admini

2003
[A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administratio

2004
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:3

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols;

2004
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat

2004
A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug

2004
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Do

2004
Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2005, Volume: 8, Issue:2

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr

2005
Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
    International journal of clinical oncology, 2005, Volume: 10, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-R

2005
Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Oncology, 2005, Volume: 69, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb

2005
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
    Oncology reports, 2006, Volume: 15, Issue:4

    Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under

2006
[Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu

2006
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D

2006
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio

2006
[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug

2006
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
    British journal of cancer, 2006, Dec-18, Volume: 95, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2006
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
    British journal of cancer, 2006, Dec-18, Volume: 95, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations;

2006
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:5

    Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea;

2008
A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    The New England journal of medicine, 2007, Nov-01, Volume: 357, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2007
A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:12

    Topics: Administration, Oral; Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combi

2007
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free

2008
Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Dr

2009
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administrati

1998
[A new therapeutic approach to advanced and recurrent gastric cancer by TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr

2001
[The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Femal

2002

Other Studies

196 other studies available for oxonic acid and Local Neoplasm Recurrence

ArticleYear
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
    Oncology, 2021, Volume: 99, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2021
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
    Nagoya journal of medical science, 2021, Volume: 83, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Drug Combinations; Fluorouraci

2021
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
    Medicine, 2021, Dec-23, Volume: 100, Issue:51

    Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm

2021
CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer.
    The Journal of surgical research, 2020, Volume: 245

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2020
Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
    Annals of surgical oncology, 2020, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2020
[A Case of Large-Cell Neuroendocrine Carcinoma of the Stomach with Multiple Liver Metastases That Show Complete Response to Multidisciplinary Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Gastrectomy; H

2019
The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients.
    Medicine, 2019, Volume: 98, Issue:44

    Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; F

2019
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dr

2019
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2020
[Preoperative C-reactive protein predicts recurrence after curative resection in advanced gastric cancer patients receiving postoperative adjuvant chemotherapy using S-1].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2020, Volume: 117, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Chemotherapy, Adjuvant; Drug Com

2020
Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Asia-Pacific journal of clinical oncology, 2020, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2020
Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
    Scientific reports, 2020, 02-21, Volume: 10, Issue:1

    Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Disease-Free Survival; D

2020
Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
    Anticancer research, 2020, Volume: 40, Issue:3

    Topics: Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, L

2020
[A Case of Successful Surgical Treatment for Paraaortic Lymph Nodes Recurrence of Gallbladder Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Drug Combinations; Gallbladder Neoplasms; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic

2019
[A Case Report of Advanced Gastric Cancer with Synchronous Liver Metastasis Treated with Conversion Surgery after S-1 plus Oxaliplatin Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Liver

2019
[A Case with Three Resections of the Pulmonary Metastases of a Distal Bile Duct Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts; Drug Combinations; Humans; L

2019
[A Case of Curative Resection of Locally Advanced Gastric Cancer after Nutrition Therapy and Chemotherapy with S-1 and Oxaliplatin Using Elemental Diet Tube].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Food, Formulated; Gastrecto

2019
[A Case of Curatively Resected Locally Recurrent Rectal Mucinous Adenocarcinoma Followed by Preoperative Chemoradiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Hum

2019
[A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplas

2019
[A Case of Advanced Gastric Cancer with Liver Metastases Treated with Curative Conversion Therapy after S-1 plus Oxaliplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Liver Neopla

2019
[A Case of Recurrent Gastric Cancer with Clinical Complete Response after Ramucirumab plus Paclitaxel Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Gastre

2019
[A Case of Gastric Endocrine Carcinoma with a Huge Liver Metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Gastrectomy; Humans; Liver Neoplasm

2019
[A Case of Advanced Gastric Cancer with Right Gastroepiploic Vein Tumor Thrombus Treated by Preoperative S-1 plus CDDP That Resulted in Pathological Complete Response].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hum

2019
Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity score matching method.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2020
[A Case of Long-Term Survival with Far Advanced Gastric Cancer after Multidisciplinary Treatments, including Conversion Surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphatic Metastasis; Mal

2020
[Long-Term Survival for a Patient with StageⅣ Gastric Cancer with Multiple Liver Metastases for Ten Years Who Was Treated with Only S-1Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:4

    Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans;

2020
Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.
    International journal of clinical oncology, 2020, Volume: 25, Issue:10

    Topics: Aged; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neo

2020
Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged

2020
Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
    The Journal of surgical research, 2020, Volume: 256

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Ch

2020
[A Long Term Survival Case of Gastric Cancer with Peritoneal Dissemination Responding to Intraperitoneal Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Human

2020
Adjuvant Chemotherapy vs. Surgery Alone for pT3N0M0 Gastric Cancer.
    Annals of surgical oncology, 2021, Volume: 28, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Gastrectomy; Humans; Neoplas

2021
[A Case of Type 4 Gastric Cancer with Peritoneal Dissemination Successfully Treated with Conversion Surgery after Intensive S-1 plus Oxaliplatin Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans

2021
[A Case of Advanced Gastric Cancer with Extensive Lymph Node Metastasis That Showed pCR to Preoperative Chemotherapy Containing SP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrect

2020
[A Long-Survived Case of Gastric Cancer with Multiple Liver Metastases Who Underwent Gastrectomy and Received Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hum

2020
[Pathological Complete Response in a Case of Advanced Gastric Cancer with Para-Aortic Lymph Nodes Metastasis Treated by Preoperative Chemotherapy with S-1 and Oxaliplatin(SOX Therapy)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Lymph

2020
Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
    Oncology, 2021, Volume: 99, Issue:6

    Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Gastrectomy;

2021
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
    Investigational new drugs, 2021, Volume: 39, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Ne

2021
[A Long‒Term Survival Case of Gastric Cancer with Disseminated Intravascular Coagulation due to Myelocarcinomatosis Treated with S‒1 plus Oxaliplatin Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:5

    Topics: Adult; Disseminated Intravascular Coagulation; Drug Combinations; Humans; Male; Neoplasm Recurrence,

2021
Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    BMC cancer, 2021, May-26, Volume: 21, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Ch

2021
Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
    Anticancer research, 2021, Volume: 41, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; M

2021
[Choroidal metastasis from gastric cancer 8 years after surgery].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2021, Volume: 118, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choroid; Drug Combinations;

2021
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati

2021
Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer.
    International journal of clinical oncology, 2021, Volume: 26, Issue:11

    Topics: Chemoradiotherapy, Adjuvant; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; P

2021
High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
    Oncology, 2021, Volume: 99, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2021
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
    Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2017
Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018, Volume: 24, Issue:4

    Topics: Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Ant

2018
Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer.
    Anticancer research, 2017, Volume: 37, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2017
Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report.
    Medicine, 2017, Volume: 96, Issue:51

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Drug Combinations; Follow-Up Studies; Humans; Male; Ne

2017
Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer.
    Die Pharmazie, 2018, 03-05, Volume: 73, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H

2018
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
    Annals of surgical oncology, 2018, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2018
Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018, Volume: 21, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combin

2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
    International journal of clinical oncology, 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Papillary; Carcino

2018
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
    Surgery today, 2018, Volume: 48, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma,

2018
Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
    Anticancer research, 2018, Volume: 38, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality

2018
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
    Anticancer research, 2018, Volume: 38, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Stud

2018
Successful treatment of microcystic adnexal carcinoma on the philtrum with oral S-1 monotherapy.
    The Journal of dermatology, 2019, Volume: 46, Issue:6

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Skin Appendage; Chemotherapy

2019
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2018
[A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Treated with Conversion Surgery after S-1 plus Oxaliplatin Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Lymph Node Excision; Lymp

2018
[A Case of Locally Advanced Gastric Cancer Treated with Chemoradiotherapy before Surgical Resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Gastrectomy; Humans

2018
[Three Cases of Advanced Gastric Cancer with Peritoneal Dissemination Successfully Treated with S-1 and Docetaxel Combination Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Gastrect

2018
[A Case of Pancreatic Acinar Cell Carcinoma in a Young Woman without Recurrence after Systemic Chemotherapy Using S-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Adult; Carcinoma, Acinar Cell; Drug Combinations; Female; Humans; Neoplasm Recurrence, Local; Oxonic

2018
[Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug C

2018
[Adjuvant Chemotherapy and the Prognosis of ypStageⅠ Gastric Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations

2019
[Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Laparoscopy;

2019
Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019, Volume: 22, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectom

2019
[A Case of Recurrent Gastric Cancer Successfully Treated by S-1 Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:2

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans

2019
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Auris, nasus, larynx, 2020, Volume: 47, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C

2020
Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study.
    International journal of clinical oncology, 2019, Volume: 24, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2019
[A Case of Advanced Gastric Cancer with Pathological Complete Response after Chemotherapy(S-1/Cisplatin)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrect

2019
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
    Anticancer research, 2019, Volume: 39, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination

2019
Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer.
    Surgery today, 2019, Volume: 49, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

2019
Histopathological changes in tumor budding between biopsy and resected specimens from patients treated with preoperative S-1 chemotherapy for oral cancer.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2019, Volume: 48, Issue:10

    Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Drug Combinations; Humans; Mouth

2019
A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.
    International journal of clinical oncology, 2014, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Co

2014
[A case of a septic pulmonary embolism-related implanted central venous port].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Catheters, I

2013
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom

2014
Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
    International journal of clinical oncology, 2014, Volume: 19, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

2014
Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Anticancer research, 2013, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2013
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
    Oncology, 2013, Volume: 84, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2013
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations

2014
Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
    Oncology reports, 2014, Volume: 31, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati

2014
Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
    Annals of surgical oncology, 2014, Volume: 21, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio

2014
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cispl

2014
Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014, Volume: 190, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidin

2014
Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
    Oncology research and treatment, 2014, Volume: 37, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy;

2014
Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.
    Oncology research and treatment, 2014, Volume: 37, Issue:1-2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Huma

2014
Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.
    Auris, nasus, larynx, 2014, Volume: 41, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Drug Combina

2014
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
    Anticancer research, 2014, Volume: 34, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Fem

2014
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
    Annals of surgical oncology, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th

2015
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2014
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Dasatinib; Drug Combinat

2014
Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
    World journal of surgical oncology, 2014, Dec-30, Volume: 12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2014
Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.
    Pathology oncology research : POR, 2015, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combin

2015
Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva

2015
[A case of hepatic metastases from colorectal cancer in a long-term survivor undergoing local combined modality therapy for repeated local recurrences].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Aged, 80 and over; Catheter Ablation; Combined Modality Therapy; Drug Combinations; Embolization, Th

2014
[Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Recurrence

2014
Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Surgery, 2015, Volume: 158, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combi

2015
S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
    Annals of surgical oncology, 2016, Volume: 23, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Com

2016
[A Case of Unresectable Local Recurrence of Gastric Cancer Successfully Resected after Pre-Operative Chemotherapy with Trastuzumab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations;

2015
Repeated Hepatectomy for Recurrent Intrahepatic Cholangiolocellular Carcinoma: Report of a Case.
    The Tokai journal of experimental and clinical medicine, 2016, Jun-20, Volume: 41, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycyt

2016
Usefulness of chemoradiotherapy for inoperable gastric cancer.
    Annals of the Royal College of Surgeons of England, 2017, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2017
Achieved good response of S-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget's disease.
    The Journal of dermatology, 2017, Volume: 44, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Fatal Outcome; H

2017
Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2017, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Chemotherap

2017
[A case report of S-1 single effective use as third-line chemotherapy and re-challenge in a recurrent squamous cell lung cancer patient].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; D

2008
[A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Drug C

2008
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
    Breast cancer (Tokyo, Japan), 2009, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre

2009
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb

2008
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy

2009
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo

2008
[A case of early recurrence with multiple liver metastases after curative operation of gastric cancer successfully treated by S-1/CDDP combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combination

2008
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinati

2009
S-1 monotherapy in patients with advanced biliary tract cancer.
    Oncology, 2009, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neopl

2009
Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2009, Volume: 15, Issue:5

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Sq

2009
[Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:11

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Anti

2009
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon H

2010
[Complete response by S-1 with multiple pulmonary metastases 4 years after lung resection-a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Humans; Lung Neo

2009
[A case of cancer successfully treated by chemotherapy of S-1 as first-line chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13

    Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Drug Combinations; Humans;

2009
[A resected case of pathologically complete response of a pelvic recurrence from rectal cancer after chemoradiotherapy with S-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy;

2009
[A case of locally recurrent rectal cancer responding to radiation and chemotherapy with S-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Humans; Male; Middle

2009
[A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Aorta, Abdominal; Chemotherapy, Adjuvant; Drug Combinations; Humans

2009
[A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2009
[A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Carnitine O-Palmitoyltransferase; Drug Combinations; Duodenal Neopl

2009
[A long-term survival case of liver metastasis of gastric cancer under interdisciplinary therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2009
[A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2009
[A case of complete response to S-1 therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Hu

2009
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2010
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2010
[A successful case of S-1 chemotherapy for bilateral pulmonary recurrence of hepatocellular carcinoma long after hepatectomy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3

    Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Humans; Liver Neopl

2010
Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP.
    BMC cancer, 2010, Apr-07, Volume: 10

    Topics: Antimetabolites, Antineoplastic; Dose-Response Relationship, Radiation; Drug Combinations; Fluorodeo

2010
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
    World journal of surgical oncology, 2010, May-19, Volume: 8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Comb

2010
[Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Head

2010
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2010
[A case with local recurrence of rectal cancer that responded to S-1 and PSK with long-term complete response].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Adenocarcinoma, Mucinous; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine

2010
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcino

2011
Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2010, Volume: 13, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fem

2010
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:13

    Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female;

2010
[A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

2010
[A case of type 4 gastric cancer with positive peritoneal lavage cytology, which relapsed at the peritoneum at the time of seven years and eight months after resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy;

2010
[A case of advanced gastric cancer successfully treated with chemoradiotherapy targeting for recurrent lymph node metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2010
[A case of local relapsed rectal cancer responding to low-dose S-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2010
[A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2010
Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2011, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug C

2011
Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2011, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2011
Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination.
    The Tokai journal of experimental and clinical medicine, 2011, Apr-20, Volume: 36, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Cisplatin; Dr

2011
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2012
Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female;

2011
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
    Clinical lung cancer, 2012, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2012
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug

2011
Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Co

2012
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 3

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents,

2011
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In

2012
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2013, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy

2013
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:115

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; C

2012
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
    International journal of clinical oncology, 2013, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine;

2013
Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report.
    BMC gastroenterology, 2012, Jul-31, Volume: 12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2012
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr

2012
Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer.
    The Annals of otology, rhinology, and laryngology, 2012, Volume: 121, Issue:8

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy,

2012
Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer.
    Journal of pharmacy practice, 2013, Volume: 26, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug Combination

2013
[Complete response in a case of recurrent gastric cancer treated with TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Sch

2002
[Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:11

    Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Co

2002
S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2003, Volume: 6 Suppl 1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug

2003
Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2003, Volume: 6 Suppl 1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; D

2003
[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Conjunctivitis; Drug Combinations; Foot Derma

2003
[A case of recurrent early gastric cancer with peritonitis carcinomatosa successfully treated with TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combina

2003
[A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration

2003
[Clinical evaluation, including QOL of TS-1 for patients with locally advanced or recurrent gastric cancer at ambulatory setting].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:10

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administra

2003
[TS-1 and lentinan combination immunochemotherapy for advanced or recurrent gastric cancer: a preliminary report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule;

2003
[Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinatio

2003
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedu

2004
[A case of TS-1 resistant recurrent gastric cancer responding to TS-1 +CPT-11 combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug

2004
[A case of recurrent gallbladder cancer responding to combination chemotherapy of TS-1 and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Diarrhea

2004
[A case of recurrent gastric cancer tolerant to TS-1 therapy successfully treated by TS-1 combined with docetaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administrati

2004
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined M

2004
[Two cases of advanced and recurrent gastric cancer treated with the combination of chemotherapy and radiation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinati

2004
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati

2004
[Results of treatment of far advanced and recurrent stomach cancer with TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Sched

2005
[Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther

2005
[Clinical study of TS-1 for inoperative and recurrent gastric cancer and evaluation of long survival cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans;

2005
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic;

2005
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Co

2006
[Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration

2006
[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9

    Topics: Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administrat

2006
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.
    Journal of gastroenterology, 2006, Volume: 41, Issue:11

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dihydrouracil Dehy

2006
Combination therapy of S-1 and CDDP for patients with colorectal cancer.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2007
Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2007, Volume: 10, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Creatinine; D

2007
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine

2007
[Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administratio

2007
[A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2007
[Prolonged complete response obtained by single agent S-1 in a case of peritoneal metastasis from gastric remnant cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:10

    Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gastric Stump; Humans; Male; Middle Aged; Neopla

2007
[Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13

    Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Drug Combinations; Fe

2007
[An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:1

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms;

2008
[A case report-the marked response to S-1 + CDDP chemotherapy for post-operative local recurrence of advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Follow-Up Stud

2007
[An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:12

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonoscopy; Drug C

2007
Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer.
    JOP : Journal of the pancreas, 2008, Mar-08, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Neoplasm Rec

2008
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Drug Combinations; Female;

2007
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla

2008